MX2019014268A - Artículos de manufactura y métodos para tratamiento usando terapia celular adoptiva. - Google Patents

Artículos de manufactura y métodos para tratamiento usando terapia celular adoptiva.

Info

Publication number
MX2019014268A
MX2019014268A MX2019014268A MX2019014268A MX2019014268A MX 2019014268 A MX2019014268 A MX 2019014268A MX 2019014268 A MX2019014268 A MX 2019014268A MX 2019014268 A MX2019014268 A MX 2019014268A MX 2019014268 A MX2019014268 A MX 2019014268A
Authority
MX
Mexico
Prior art keywords
methods
articles
manufacture
cell therapy
treatment
Prior art date
Application number
MX2019014268A
Other languages
English (en)
Inventor
Tina Albertson
Claire L Sutherland
Brian Christin
Christopher Glen Ramsborg
Clinton Weber
Jacob Randolph Garcia
Rachel K Yost
Mark J Gilbert
He Li
Original Assignee
Juno Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Juno Therapeutics Inc filed Critical Juno Therapeutics Inc
Publication of MX2019014268A publication Critical patent/MX2019014268A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A61K39/464412—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/53—Colony-stimulating factor [CSF]
    • G01N2333/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5428—IL-10
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se proporcionan métodos de terapia celular adoptiva que implican la administración de dosis de células para tratar enfermedades y condiciones, incluyendo ciertas malignidades de células B. Las células en general expresan receptores recombinantes tal como receptores quiméricos de antígeno (CAR). En algunas modalidades, los métodos son para tratar sujetos con linfoma no de Hodgkin (NHL). En algunas modalidades, los métodos son para tratar sujetos con NHL recidivante o refractario. También se proporcionan artículos de manufactura y tratamientos profilácticos en relación con los métodos de terapia adoptiva.
MX2019014268A 2017-06-02 2018-06-01 Artículos de manufactura y métodos para tratamiento usando terapia celular adoptiva. MX2019014268A (es)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201762514774P 2017-06-02 2017-06-02
US201762515530P 2017-06-05 2017-06-05
US201762521366P 2017-06-16 2017-06-16
US201762527000P 2017-06-29 2017-06-29
US201762549938P 2017-08-24 2017-08-24
US201762580425P 2017-11-01 2017-11-01
US201762593871P 2017-12-01 2017-12-01
US201762596764P 2017-12-08 2017-12-08
US201862614957P 2018-01-08 2018-01-08
PCT/US2018/035755 WO2018223101A1 (en) 2017-06-02 2018-06-01 Articles of manufacture and methods for treatment using adoptive cell therapy

Publications (1)

Publication Number Publication Date
MX2019014268A true MX2019014268A (es) 2020-08-03

Family

ID=62705744

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019014268A MX2019014268A (es) 2017-06-02 2018-06-01 Artículos de manufactura y métodos para tratamiento usando terapia celular adoptiva.

Country Status (12)

Country Link
US (3) US11413310B2 (es)
EP (1) EP3630132A1 (es)
JP (2) JP2020522489A (es)
KR (1) KR20200054160A (es)
CN (1) CN111225675B (es)
AU (1) AU2018275894A1 (es)
BR (1) BR112019025403A2 (es)
CA (1) CA3065120A1 (es)
IL (1) IL270982A (es)
MX (1) MX2019014268A (es)
PH (1) PH12019502661A1 (es)
WO (1) WO2018223101A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7057669B2 (ja) 2014-10-20 2022-04-20 ジュノー セラピューティクス インコーポレイテッド 養子細胞療法において投薬するための方法および組成物
CA3008162A1 (en) * 2014-12-15 2016-06-23 The Regents Of The University Of California Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20
US11815514B2 (en) 2015-12-04 2023-11-14 Juno Therapeutics, Inc. Methods and compositions related to toxicity associated with cell therapy
AU2018275894A1 (en) 2017-06-02 2019-12-12 Juno Therapeutics, Inc. Articles of manufacture and methods for treatment using adoptive cell therapy
US11564946B2 (en) 2017-11-01 2023-01-31 Juno Therapeutics, Inc. Methods associated with tumor burden for assessing response to a cell therapy
EP3716980A1 (en) * 2017-12-01 2020-10-07 Juno Therapeutics, Inc. Methods for dosing and for modulation of genetically engineered cells
MX2020010913A (es) 2018-04-17 2021-01-08 Celldex Therapeutics Inc Anticuerpos anti-cd27 y anti-pd-l1 y constructos biespecíficos.
US11197658B2 (en) 2018-05-18 2021-12-14 Nanobio Systems Inc. Collection and treatment of a biofluid sample
CA3117978A1 (en) * 2018-11-08 2020-05-14 Juno Therapeutics, Inc. Methods and combinations for treatment and t cell modulation
WO2020123444A1 (en) * 2018-12-11 2020-06-18 Celldex Therapeutics, Inc. Methods of using cd27 antibodies as conditioning treatment for adoptive cell therapy
TW202108150A (zh) * 2019-05-03 2021-03-01 美商凱特製藥公司 投與嵌合抗原受體免疫療法之方法
US20220401483A1 (en) * 2019-11-07 2022-12-22 Juno Therapeutics, Inc. Combination of a t cell therapy and (s)-3-[4-(4-morpholin-4-ylmethyl-benzyloxy)-l-oxo-l,3-dihydro-isoindol-2-yl]-piperidine-2,6-dione
CN115398231A (zh) * 2019-12-06 2022-11-25 朱诺治疗学股份有限公司 与治疗b细胞恶性肿瘤的细胞疗法相关的毒性和反应的相关方法
EP4103202A1 (en) * 2020-02-10 2022-12-21 The Johns Hopkins University Cancer immunotherapy using transfusions of allogeneic, tumor-specific cd4+ t cells
JP2023519098A (ja) * 2020-02-12 2023-05-10 ジュノー セラピューティクス インコーポレイテッド Ｃｄ１９指向性キメラ抗原受容体ｔ細胞組成物ならびにその方法および使用
US20210287805A1 (en) * 2020-03-11 2021-09-16 National Taiwan University Systems and methods for prognosis prediction of acute myeloid leukemia patients
EP4125951A4 (en) * 2020-04-03 2024-04-17 Trishula Therapeutics Inc COMBINATION THERAPY WITH ANTI-CD39 ANTIBODIES AND ADOPTIVE CELL THERAPY
CN115916223A (zh) * 2020-04-10 2023-04-04 朱诺治疗学股份有限公司 与用靶向b细胞成熟抗原的嵌合抗原受体工程化的细胞疗法相关的方法和用途
EP4150640A1 (en) 2020-05-13 2023-03-22 Juno Therapeutics, Inc. Methods of identifying features associated with clinical response and uses thereof
WO2021263189A1 (en) * 2020-06-25 2021-12-30 Angiocrine Bioscience, Inc. Endothelial cells for mitigation of chemotherapy-induced toxicity
WO2022187517A1 (en) * 2021-03-04 2022-09-09 New York University Methods of modulating neuronal and oligodenrocyte survival
EP4337959A1 (en) * 2021-05-11 2024-03-20 Janssen Biotech, Inc. Methods of minimizing neurotoxicity associated with chimeric antigen receptor (car) t cell therapy
CN113699123B (zh) * 2021-10-28 2022-01-25 旦旦生物科技(上海)有限公司 靶向超敏广谱溶瘤病毒制备及应用
WO2023230548A1 (en) 2022-05-25 2023-11-30 Celgene Corporation Method for predicting response to a t cell therapy

Family Cites Families (206)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US50401A (en) 1865-10-10 Washing and wringing machine
DE2117571C3 (de) 1971-04-10 1979-10-11 Bayer Ag, 5090 Leverkusen Unsymmetrische 1,4-Dihydropyridin-33-dicarbonsäureester, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel
GB2116183B (en) 1982-03-03 1985-06-05 Genentech Inc Human antithrombin iii dna sequences therefore expression vehicles and cloning vectors containing such sequences and cell cultures transformed thereby a process for expressing human antithrombin iii and pharmaceutical compositions comprising it
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
IN165717B (es) 1986-08-07 1989-12-23 Battelle Memorial Institute
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5565566A (en) 1987-04-24 1996-10-15 Discovery Therapeutics, Inc. N6 -substituted 9-methyladenines: a new class of adenosine receptor antagonists
US5298508A (en) 1988-07-19 1994-03-29 The United States Of America As Represented By The Department Of Health And Human Services Irreversible inhibitors of adenosine receptors
AU4746590A (en) 1988-12-28 1990-08-01 Stefan Miltenyi Methods and materials for high gradient magnetic separation of biological materials
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
CA2096222C (en) 1990-11-13 1998-12-29 Stephen D. Lupton Bifunctional selectable fusion genes
FR2688138B1 (fr) 1992-03-06 1995-05-05 Rhone Poulenc Rorer Sa Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la sclerose laterale amyotrophique.
US5424297A (en) 1992-04-27 1995-06-13 University Of Virginia Alumni Patents Foundation Adenosine dextran conjugates
WO1994009138A1 (en) 1992-10-20 1994-04-28 Cetus Oncology Corporation Interleukin-6 receptor antagonists
US5629327A (en) 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
WO1994025462A1 (en) 1993-05-03 1994-11-10 The United States Of America, Represented By The 8-substituted 1,3,7-trialkyl-xanthine derivatives as a2-selective adenosine receptor antagonists
EP0804590A1 (en) 1993-05-21 1997-11-05 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5504090A (en) 1994-03-30 1996-04-02 Trustees Of The University Of Pennsylvania Compositions and methods for the prevention and treatment of ischemia-reperfusion organ injury
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US5670501A (en) 1994-09-01 1997-09-23 Discovery Therapeutics, Inc. N-substituted 9-alkyladenines
WO1996013593A2 (en) 1994-10-26 1996-05-09 Procept, Inc. Soluble single chain t cell receptors
WO1996018105A1 (en) 1994-12-06 1996-06-13 The President And Fellows Of Harvard College Single chain t-cell receptor
WO1997027177A2 (en) 1996-01-29 1997-07-31 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Dihydropyridine-, pyridine-, benzopyran-4-one- and triazoloquinazoline derivatives, their preparation and their use as adenosine receptor antagonists
DE19608753C1 (de) 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
WO1997034634A1 (en) 1996-03-20 1997-09-25 Sloan-Kettering Institute For Cancer Research Single chain fv constructs of anti-ganglioside gd2 antibodies
US6281230B1 (en) 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
SK9199A3 (en) 1996-07-24 1999-07-12 Celgene Corp 2,6-dioxopiperidines, pharmaceutical composition them containing and their use
US5798368A (en) 1996-08-22 1998-08-25 Celgene Corporation Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels
HU228769B1 (en) 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
DK0920505T3 (da) 1996-08-16 2008-09-08 Schering Corp Pattedyrcelleoverfladeantigener og tilhörende reagenser
US6111090A (en) 1996-08-16 2000-08-29 Schering Corporation Mammalian cell surface antigens; related reagents
US5786360A (en) 1996-11-19 1998-07-28 Link Technology Incorporated A1 adenosine receptor antagonists
CA2305630C (en) 1997-10-02 2012-11-06 Sunol Molecular Corporation Soluble single-chain t-cell receptor proteins
EP1025228A4 (en) 1997-10-21 2002-09-18 Human Genome Sciences Inc HUMAN PROTEIN TR11, TR11SV1 AND TR11SV2 SIMILAR TO THE TUMOR NECROSIS FACTOR RECEPTOR
IL137409A0 (en) 1998-02-09 2001-07-24 Genentech Inc Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same
SK13642000A3 (sk) 1998-03-16 2001-04-09 Celgene Corporation 2-(2,6-dioxopiperidin-3-yl)izoindolínové deriváty, farmaceutický prostriedok s ich obsahom a ich použitie
ES2246567T3 (es) 1998-04-15 2006-02-16 Brigham & Womens Hospital Composiciones para receptores inhibidores de celulas t y usos de las mismas.
TR200003391T2 (tr) 1998-05-19 2001-02-21 Avidex Limited Çözünür T hücresi reseptörü
US6326390B1 (en) 1998-08-25 2001-12-04 King Pharmaceuticals Reseach And Development, Inc. Use of adenosine A3 receptor antagonists to inhibit tumor growth
JP2002524081A (ja) 1998-09-04 2002-08-06 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ 前立腺−特異的膜抗原に特異的な融合受容体およびその使用
AU2472400A (en) 1998-10-20 2000-05-08 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
US6232297B1 (en) 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US6313131B1 (en) 1999-02-16 2001-11-06 Upsher-Smith Laboratories, Inc. Method of kidney treatment
CN1342146A (zh) 1999-03-18 2002-03-27 塞尔基因公司 取代的1－氧代－和1,3－二氧代异吲哚啉及其在用于减少炎性细胞因子含量的药物组合物中的用途
US6322771B1 (en) 1999-06-18 2001-11-27 University Of Virginia Patent Foundation Induction of pharmacological stress with adenosine receptor agonists
WO2001003720A2 (en) 1999-07-12 2001-01-18 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs
US20030235908A1 (en) 2000-02-24 2003-12-25 Xcyte Therapies, Inc. Activation and expansion of cells
CA2410510A1 (en) 2000-06-02 2001-12-13 Memorial Sloan-Kettering Cancer Center Artificial antigen presenting cells and methods of use thereof
AU2001297703B2 (en) 2000-11-07 2006-10-19 City Of Hope CD19-specific redirected immune cells
US6458810B1 (en) 2000-11-14 2002-10-01 George Muller Pharmaceutically active isoindoline derivatives
US7091353B2 (en) 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
US20030045552A1 (en) 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
GB0100624D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VII
CA2439410C (en) 2001-02-27 2011-09-06 William D. Figg Analogs of thalidomide as potential angiogenesis inhibitors
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
PL208712B1 (pl) 2001-08-31 2011-05-31 Avidex Ltd Rozpuszczalny receptor komórek T (sTCR), rozpuszczalna αβ-postać receptora komórek T (sTCR), wielowartościowy kompleks receptora komórek T (TCR), sposób wykrywania kompleksów MHC-peptyd, środek farmaceutyczny zawierający sTCR i/lub wielowartościowy kompleks TCR, cząsteczka kwasu nukleinowego, wektor, komórka gospodarz, sposób otrzymywania całości lub części łańcucha α TCR albo całości lub części łańcucha β TCR, sposób otrzymywania rozpuszczalnego receptora komórek T (sTCR), sposób otrzymywania rozpuszczalnej αβ-postaci receptora komórek T (sTCR) oraz sposób wykrywania kompleksów MHC-peptyd
US7939059B2 (en) 2001-12-10 2011-05-10 California Institute Of Technology Method for the generation of antigen-specific lymphocytes
AU2002356962C1 (en) 2001-12-12 2008-05-01 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
NZ605429A (en) 2002-09-06 2014-08-29 Amgen Inc Therapeutic human anti-il-1r1 monoclonal antibody
US20040047858A1 (en) 2002-09-11 2004-03-11 Blumberg Richard S. Therapeutic anti-BGP(C-CAM1) antibodies and uses thereof
AU2003271904B2 (en) 2002-10-09 2009-03-05 Adaptimmune Limited Single chain recombinant T cell receptors
AU2003288675B2 (en) 2002-12-23 2010-07-22 Medimmune Limited Antibodies against PD-1 and uses therefor
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
AU2004244626A1 (en) 2003-05-23 2004-12-09 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services GITR ligand and GITR ligand-related molecules and antibodies and uses thereof
US20050048054A1 (en) 2003-07-11 2005-03-03 Shino Hanabuchi Lymphocytes; methods
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
WO2005055808A2 (en) 2003-12-02 2005-06-23 Genzyme Corporation Compositions and methods to diagnose and treat lung cancer
GB0409799D0 (en) 2004-04-30 2004-06-09 Isis Innovation Method of generating improved immune response
WO2006083289A2 (en) 2004-06-04 2006-08-10 Duke University Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
WO2006009755A2 (en) 2004-06-17 2006-01-26 Plexxikon, Inc. Azaindoles modulating c-kit activity and uses therefor
JP5563194B2 (ja) 2004-06-29 2014-07-30 イムノコア リミテッド 改変ｔ細胞レセプターを発現する細胞
US7244759B2 (en) 2004-07-28 2007-07-17 Celgene Corporation Isoindoline compounds and methods of making and using the same
US7645755B2 (en) 2004-10-22 2010-01-12 Janssen Pharmaceutical N.V. Inhibitors of c-fms kinase
EP2343320B1 (en) 2005-03-25 2017-10-25 GITR, Inc. Anti-gitr antibodies and uses thereof
CN109485727A (zh) 2005-05-09 2019-03-19 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
PL1899364T3 (pl) 2005-05-17 2020-08-24 University Of Connecticut Kompozycje i sposoby immunomodulacji w organizmie
MX2007015942A (es) 2005-07-01 2008-03-07 Medarex Inc Anticuerpos monoclonales humanos para ligandos 1 (pd-l1) de muerte programada.
JP5709356B2 (ja) 2006-01-13 2015-04-30 アメリカ合衆国 哺乳動物細胞における発現のためのコドン最適化ＩＬ−１５およびＩＬ−１５Ｒ−α遺伝子
US20110212086A1 (en) 2006-01-19 2011-09-01 Genzyme Corporation GITR Antibodies For The Treatment of Cancer
EP2526933B1 (en) 2006-09-22 2015-02-25 Pharmacyclics, Inc. Inhibitors of Bruton's tyrosine kinase
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
LT2653873T (lt) 2007-02-08 2022-10-10 Biogen Ma Inc. Kompozicijos ir naudojimas, skirti išsėtinei sklerozei gydyti
EP2111231A4 (en) 2007-02-13 2010-12-15 Univ Northeastern METHODS AND COMPOSITIONS FOR IMPROVING IMMUNE RESPONSES
WO2008121420A1 (en) 2007-03-30 2008-10-09 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred t lymphocytes
US7615883B2 (en) 2007-06-06 2009-11-10 Meheen H Joe Wind driven venturi turbine
DK2170959T3 (da) 2007-06-18 2014-01-13 Merck Sharp & Dohme Antistoffer mod human programmeret dødsreceptor pd-1
NZ582330A (en) 2007-06-27 2012-05-25 Marinepolymer Tech Inc COMPLEXES OF IL-15 AND IL-15Ra (RECEPTOR ALPHA) AND USES THEREOF
ES2591281T3 (es) 2007-07-12 2016-11-25 Gitr, Inc. Terapias de combinación que emplean moléculas de enlazamiento a GITR
CA2703947C (en) 2007-10-26 2018-12-04 Governing Council Of The University Of Toronto Therapeutic and diagnostic methods using tim-3
ES2640216T3 (es) 2007-12-07 2017-11-02 Miltenyi Biotec Gmbh Sistemas y métodos para procesamiento de células
US8479118B2 (en) 2007-12-10 2013-07-02 Microsoft Corporation Switching search providers within a browser search box
AU2009209251B8 (en) 2008-01-28 2015-03-26 Medimmune Limited Stabilized Angiopoietin-2 antibodies and uses thereof
WO2009099553A2 (en) 2008-02-01 2009-08-13 The Regents Of The University Of California Use of kinase inhibitor in treatment of atherosclerosis
ES2639857T3 (es) 2008-02-11 2017-10-30 Cure Tech Ltd. Anticuerpos monoclonales para el tratamiento del tumor
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
US20120164718A1 (en) 2008-05-06 2012-06-28 Innovative Micro Technology Removable/disposable apparatus for MEMS particle sorting device
JP5173594B2 (ja) 2008-05-27 2013-04-03 キヤノン株式会社 管理装置、画像形成装置及びそれらの処理方法
GB0906579D0 (en) 2009-04-16 2009-05-20 Vernalis R&D Ltd Pharmaceuticals, compositions and methods of making and using the same
JP2011526794A (ja) 2008-07-02 2011-10-20 エマージェント プロダクト デベロップメント シアトル， エルエルシー ＴＧＦ−βアンタゴニスト多重標的結合性分子
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
AU2009288289B2 (en) 2008-08-25 2012-11-08 Amplimmune, Inc. PD-1 antagonists and methods of use thereof
CA2734908A1 (en) 2008-08-25 2010-03-11 Amplimmune, Inc. Compositions of pd-1 antagonists and methods of use
ES2961498T3 (es) 2008-08-26 2024-03-12 Hope City Método y composiciones para el funcionamiento mejorado del efecto antitumoral de las células T
JPWO2010030002A1 (ja) 2008-09-12 2012-02-02 国立大学法人三重大学 外来性ｇｉｔｒリガンド発現細胞
EP2341771A4 (en) 2008-09-19 2012-08-15 Paratek Pharm Innc TETRACYCLINE COMPOUNDS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND RELATED THERAPEUTIC METHODS
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
KR101695329B1 (ko) 2008-11-07 2017-01-23 암젠 리서치 (뮌헨) 게엠베하 소아 급성 림프구성 백혈병의 치료방법
WO2010065959A1 (en) 2008-12-05 2010-06-10 Northeastern University Method of preparing adenosine-resistant anti-tumor t lymphocytes for adoptive immunotherapy
TWI686405B (zh) 2008-12-09 2020-03-01 建南德克公司 抗ｐｄ-ｌ１抗體及其於增進ｔ細胞功能之用途
EP3192811A1 (en) 2009-02-09 2017-07-19 Université d'Aix-Marseille Pd-1 antibodies and pd-l1 antibodies and uses thereof
RU2598710C2 (ru) 2009-04-30 2016-09-27 Тел Хашомер Медикал Рисерч Инфрастракче Энд Сервисиз Лтд. Антитела к сеасам1 и способы их использования
AU2010282280B2 (en) 2009-08-14 2016-06-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of IL-15 to increase thymic output and to treat lymphopenia
KR101790802B1 (ko) 2009-09-03 2017-10-27 머크 샤프 앤드 돔 코포레이션 항-ｇｉｔｒ 항체
CA2777053A1 (en) 2009-10-06 2011-04-14 The Board Of Trustees Of The University Of Illinois Human single-chain t cell receptors
GB0919054D0 (en) 2009-10-30 2009-12-16 Isis Innovation Treatment of obesity
JP5956342B2 (ja) 2009-11-03 2016-07-27 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ 形質導入Ｔ細胞選択のためのトランケート上皮増殖因子レセプタ（ＥＧＦＲｔ）
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
EP3112382A1 (en) 2009-12-29 2017-01-04 Emergent Product Development Seattle, LLC Heterodimer binding proteins and uses thereof
CA3154024C (en) 2010-06-03 2024-02-27 Pharmacyclics Llc Use of inhibitors of bruton's tyrosine kinase (btk) in the treatment of relapsed or refractory follicular lymphoma
WO2011159877A2 (en) 2010-06-18 2011-12-22 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
BR122021026169B1 (pt) 2010-12-09 2023-12-12 The Trustees Of The University Of Pennsylvania Uso de uma célula
BR112013024157A2 (pt) 2011-03-22 2016-12-06 Mucosis Bv composições imunogênicas em forma particulada e métodos para produção destas
ES2841983T3 (es) * 2011-03-23 2021-07-12 Hutchinson Fred Cancer Res Método y composiciones para inmunoterapia celular
EP3632463A1 (en) 2011-04-08 2020-04-08 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
ES2622527T3 (es) 2011-05-05 2017-07-06 Novartis Ag Inhibidores de CSF-1R para el tratamiento de tumores de cerebro
US8398282B2 (en) 2011-05-12 2013-03-19 Delphi Technologies, Inc. Vehicle front lighting assembly and systems having a variable tint electrowetting element
US8841418B2 (en) 2011-07-01 2014-09-23 Cellerant Therapeutics, Inc. Antibodies that specifically bind to TIM3
US20130108641A1 (en) 2011-09-14 2013-05-02 Sanofi Anti-gitr antibodies
WO2013054320A1 (en) 2011-10-11 2013-04-18 Tel Hashomer Medical Research Infrastructure And Services Ltd. Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
BR112014011417B1 (pt) 2011-11-11 2021-10-13 Fred Hutchinson Cancer Research Center Polipeptídeo isolado capaz de elicitar uma resposta de célula t antígeno-específica para ciclina a1 humana, composição imunogênica compreendendo o referido polipeptídeo, bem como método para preparar células apresentadoras de antígeno, antígeno-pulsadas,e uso destas para superexpressão de ccna1
CA2892371C (en) 2011-12-01 2021-01-19 The Brigham And Women's Hospital, Inc. Anti-ceacam1 recombinant antibodies for cancer therapy
WO2013109759A1 (en) 2012-01-17 2013-07-25 Northeastern University Methods and compositions for expanding immunosuppressive t regulatory cells in vitro and uses thereof
EP2814846B1 (en) 2012-02-13 2020-01-08 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
WO2013126726A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
US20150119267A1 (en) 2012-04-16 2015-04-30 Sloan-Kettering Institute For Cancer Research Inhibition of colony stimulating factor-1 receptor signaling for the treatment of brain cancer
KR20150009556A (ko) 2012-05-03 2015-01-26 프레드 헛친슨 켄서 리서치 센터 증강된 친화성 t　세포 수용체 및 이의 제조 방법
US9296753B2 (en) 2012-06-04 2016-03-29 Pharmacyclics Llc Crystalline forms of a Bruton's tyrosine kinase inhibitor
GB201211310D0 (en) 2012-06-26 2012-08-08 Chroma Therapeutics Ltd CSF-1R kinase inhibitors
LT3338794T (lt) 2012-07-13 2020-05-25 The Trustees Of The University Of Pennsylvania Car priešnavikinio aktyvumo toksiškumo reguliavimas
EP3698809A1 (en) 2012-07-31 2020-08-26 The Brigham & Women's Hospital, Inc. Modulation of the immune response using agents binding tim-3 and ceacam-1
WO2014031687A1 (en) 2012-08-20 2014-02-27 Jensen, Michael Method and compositions for cellular immunotherapy
US9365641B2 (en) 2012-10-01 2016-06-14 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting stromal cells for the treatment of cancer
CN112430580A (zh) 2012-10-02 2021-03-02 纪念斯隆-凯特琳癌症中心 用于免疫疗法的组合物和方法
EP2906241B1 (en) 2012-10-12 2020-01-08 The Brigham and Women's Hospital, Inc. Enhancement of the immune response
JP6338252B2 (ja) 2012-10-24 2018-06-06 アメリカ合衆国 Ｍ９７１キメラ抗原受容体
CN104781789B (zh) 2012-12-20 2018-06-05 三菱电机株式会社 车载装置
CN103145849B (zh) 2013-02-18 2014-06-11 冯振卿 嵌合抗原受体及其用途
RU2019137208A (ru) 2013-02-20 2020-02-19 Новартис Аг ЛЕЧЕНИЕ РАКА С ИСПОЛЬЗОВАНИЕМ ХИМЕРНОГО АНТИГЕНСПЕЦИФИЧЕСКОГО РЕЦЕПТОРА НА ОСНОВЕ ГУМАНИЗИРОВАННОГО АНТИТЕЛА ПРОТИВ EGFRvIII
AU2014231709A1 (en) 2013-03-15 2015-10-15 Stemcell Technologies Inc. Compositions and methods for obtaining enriched mesenchymal stem cell cultures
TWI654206B (zh) 2013-03-16 2019-03-21 諾華公司 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
CA2913052A1 (en) 2013-05-24 2014-11-27 Board Of Regents, The University Of Texas System Chimeric antigen receptor-targeting monoclonal antibodies
US9108442B2 (en) 2013-08-20 2015-08-18 Ricoh Company, Ltd. Image forming apparatus
US9512084B2 (en) 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
MX2016007239A (es) 2013-12-06 2017-01-05 Celgene Corp Metodos para determinar la eficacia del farmaco para el tratamiento de linfoma difuso de celulas b grandes, mieloma multiple, y canceres mieloides.
SG10201804439PA (en) 2013-12-20 2018-06-28 Hutchinson Fred Cancer Res Tagged chimeric effector molecules and receptors thereof
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
TWI777174B (zh) 2014-03-14 2022-09-11 瑞士商諾華公司 針對lag-3之抗體分子及其用途
KR20240042250A (ko) * 2014-04-07 2024-04-01 노파르티스 아게 항-cd19 키메라 항원 수용체를 사용한 암의 치료
JP6788573B6 (ja) * 2014-04-10 2020-12-16 シアトル チルドレンズ ホスピタル， ディービーエー シアトル チルドレンズ リサーチ インスティテュート メトトレキサートによる選択と組み合わせたＳｌｅｅｐｉｎｇ Ｂｅａｕｔｙトランスポゾンによる遺伝子改変Ｔ細胞の製造
KR20220136455A (ko) * 2014-04-23 2022-10-07 주노 쎄러퓨티크스 인코퍼레이티드 입양 치료용 면역 세포 집단의 단리, 배양 및 유전자 조작 방법
US10301370B2 (en) 2014-05-02 2019-05-28 The Trustees Of The University Of Pennsylvania Compositions and methods of chimeric autoantibody receptor T cells
MX2017001011A (es) * 2014-07-21 2018-05-28 Novartis Ag Tratamiento de cancer de usando un receptor quimerico de antigeno anti-bcma.
US20170209492A1 (en) 2014-07-31 2017-07-27 Novartis Ag Subset-optimized chimeric antigen receptor-containing t-cells
TWI805109B (zh) 2014-08-28 2023-06-11 美商奇諾治療有限公司 對cd19具專一性之抗體及嵌合抗原受體
JP7057669B2 (ja) 2014-10-20 2022-04-20 ジュノー セラピューティクス インコーポレイテッド 養子細胞療法において投薬するための方法および組成物
AU2015343121B2 (en) * 2014-11-05 2020-06-18 Juno Therapeutics, Inc. Methods for transduction and cell processing
US9713375B1 (en) 2015-02-26 2017-07-25 Brett Einar Rahm Collapsible portable table
EP3280795B1 (en) 2015-04-07 2021-03-24 Novartis AG Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
MX2017012939A (es) 2015-04-08 2018-05-22 Novartis Ag Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19.
KR20160121732A (ko) 2015-04-10 2016-10-20 삼성에스디아이 주식회사 더미 칩 패키지, 이를 제조하는 방법, 및 이를 이용한 몰딩 평가 방법
US10786549B2 (en) * 2015-04-23 2020-09-29 Baylor College Of Medicine CD5 chimeric antigen receptor for adoptive T cell therapy
KR20220008388A (ko) * 2015-05-28 2022-01-20 카이트 파마 인코포레이티드 T 세포 요법을 위해 환자를 컨디셔닝하는 방법
BR122023022076A2 (pt) 2015-05-28 2024-01-16 Kite Pharma, Inc. Agente pré-condicionantes, seus usos e métodos para identificar uma dose de um ou mais agentes de pré-condicionamento e para verificar a eficácia dos mesmos
WO2017015427A1 (en) 2015-07-21 2017-01-26 Novartis Ag Methods for improving the efficacy and expansion of immune cells
GB201513540D0 (en) 2015-07-31 2015-09-16 King S College London Therapeutic agents
US11815514B2 (en) 2015-12-04 2023-11-14 Juno Therapeutics, Inc. Methods and compositions related to toxicity associated with cell therapy
TWI755547B (zh) 2016-01-21 2022-02-21 美商輝瑞股份有限公司 靶向表皮生長因子受體變異體iii之嵌合型抗原受體
US20210177896A1 (en) 2016-06-02 2021-06-17 Novartis Ag Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
MA45341A (fr) 2016-06-06 2019-04-10 Hutchinson Fred Cancer Res Procédés de traitement de malignités de lymphocytes b au moyen d'une thérapie cellulaire adoptive
CA3039014A1 (en) 2016-10-04 2018-04-12 Precision Biosciences, Inc. Co-stimulatory domains for use in genetically-modified cells
CA3042049A1 (en) 2016-11-03 2018-05-11 Juno Therapeutics, Inc. Combination therapy of a t cell therapy and a btk inhibitor
MX2019010171A (es) 2017-02-27 2019-10-15 Juno Therapeutics Inc Composiciones, articulos de fabricacion y metodos relacionados con la dosificacion en la terapia celular.
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
EP3621988A1 (en) 2017-05-09 2020-03-18 Bellicum Pharmaceuticals, Inc. Methods to augment or alter signal transduction
AU2018275894A1 (en) 2017-06-02 2019-12-12 Juno Therapeutics, Inc. Articles of manufacture and methods for treatment using adoptive cell therapy
CA3070575A1 (en) 2017-08-09 2019-02-14 Juno Therapeutics, Inc. Methods and compositions for preparing genetically engineered cells
WO2019032927A1 (en) 2017-08-09 2019-02-14 Juno Therapeutics, Inc. METHODS FOR PRODUCING GENETICALLY MODIFIED CELL COMPOSITIONS AND COMPOSITIONS THEREOF
CN111373030A (zh) 2017-09-01 2020-07-03 隆萨沃克斯维尔股份有限公司 端到端细胞治疗自动化
WO2019090003A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Chimeric antigen receptors specific for b-cell maturation antigen (bcma)
EP3716980A1 (en) 2017-12-01 2020-10-07 Juno Therapeutics, Inc. Methods for dosing and for modulation of genetically engineered cells
EP3720480A2 (en) 2017-12-08 2020-10-14 Juno Therapeutics, Inc. Phenotypic markers for cell therapy and related methods
EP3787751A1 (en) 2018-05-03 2021-03-10 Juno Therapeutics, Inc. Combination therapy of a chimeric antigen receptor (car) t cell therapy and a kinase inhibitor
EP3801769A1 (en) 2018-05-25 2021-04-14 Novartis AG Combination therapy with chimeric antigen receptor (car) therapies
WO2019232479A2 (en) 2018-06-01 2019-12-05 Fred Hutchinson Cancer Research Center Biomarkers, uses thereof for selecting immunotherapy intervention, and immunotherapy methods
AU2019387497A1 (en) 2018-11-30 2021-06-24 Juno Therapeutics, Inc. Methods for treatment using adoptive cell therapy
KR20210110811A (ko) 2018-11-30 2021-09-09 주노 쎄러퓨티크스 인코퍼레이티드 입양 세포 요법에서 ｂ 세포 악성 종양의 투약 및 치료 방법
CN114901295A (zh) 2019-11-06 2022-08-12 凯德药业股份有限公司 嵌合抗原受体t细胞疗法
AU2021209940A1 (en) 2020-01-24 2022-08-04 Juno Therapeutics, Inc. Methods for dosing and treatment of follicular lymphoma and marginal zone lymphoma in adoptive cell therapy

Also Published As

Publication number Publication date
EP3630132A1 (en) 2020-04-08
AU2018275894A1 (en) 2019-12-12
WO2018223101A1 (en) 2018-12-06
KR20200054160A (ko) 2020-05-19
US20240115612A1 (en) 2024-04-11
BR112019025403A2 (pt) 2020-08-18
CN111225675B (zh) 2024-05-03
JP2020522489A (ja) 2020-07-30
US20200147136A1 (en) 2020-05-14
CA3065120A1 (en) 2018-12-06
RU2019144333A3 (es) 2022-03-18
RU2019144333A (ru) 2021-07-09
IL270982A (en) 2020-01-30
CN111225675A (zh) 2020-06-02
JP2022180389A (ja) 2022-12-06
US11413310B2 (en) 2022-08-16
US11944647B2 (en) 2024-04-02
US20230149458A1 (en) 2023-05-18
PH12019502661A1 (en) 2020-06-08

Similar Documents

Publication Publication Date Title
PH12019502661A1 (en) Articles of manufacture and methods for treatment using adoptive cell therapy
WO2017214207A8 (en) Methods for the treatment of b cell malignancies using adoptive cell therapy
PH12020551923A1 (en) Methods and compositions for treating cancer
JOP20200292A1 (ar) Bcma / cd3 و gprdc5d / cd3 مضادات غير محددة للاستخدام في علاج السرطان
NZ765695A (en) Immune cell organoid co-cultures
MX2020008977A (es) Formulaciones de anticuerpos de her2 subcutaneas.
WO2020092848A3 (en) Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
WO2020113194A3 (en) Methods for treatment using adoptive cell therapy
WO2018068008A8 (en) T cells expressing membrane-anchored il-12 for the treatment of cancer
PH12021551036A1 (en) Anti-liv1 immune cell cancer therapy
PH12020550598A1 (en) Methods and compositions for dosing of allogeneic chimeric antigen receptor t cells
MX2022000726A (es) Anticuerpos inmunomoduladores y metodos de uso de los mismos.
MX2021006244A (es) Metodos de dosificacion y tratamiento de canceres de celulas b en terapia celular adoptiva.
MX2021015317A (es) Terapia de combinacion de una terapia citotoxica mediada por celulas y un inhibidor de una proteina de la familia bcl2 de prosupervivencia.
WO2018009528A8 (en) Combination cancer immunotherapies with arginine depletion agents
PH12021551047A1 (en) Anti-ptk7 immune cell cancer therapy
TR201811308T4 (tr) Kanser kok hücrelerini azaltan anti-emp2 tedavisi.
MX2021001517A (es) Terapia basada en microarn dirigida contra canceres positivos para proteina citosolica de linfocito 1 (lcp-1).
WO2019112978A3 (en) Anti-dclk1 antibodies and chimeric antigen receptors, and compositions and methods of use thereof
NZ625758A (en) Method for treating breast cancer
WO2019070161A3 (en) Articles and methods directed to personalized therapy of cancer
BR112022010345A2 (pt) Tratamento envolvendo células efectoras imune projetadas por receptores de antígeno
ZA201907623B (en) T cells with reduced surface fucosylation and methods of making and using the same
MX2021003734A (es) Métodos de tratamiento del linfoma de linfocitos t periférico mediante terapia con conjugado fármaco-anticuerpo anti-cd30.
ZA201907369B (en) Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment